Pulmonary rehabilitation (PR), including breath control exercises, can improve lung function in long COVID patients after only 4 to 8 weeks, according to a study in Therapeutic Advances in Respiratory ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

In the treatment of COPD exacerbations ... the lowest dose and shortest duration of corticosteroid therapy that will provide therapeutic benefit should be chosen. The literature suggests that ...

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

A therapy using a patient's own proximal basal stem cells shows promise to treat idiopathic pulmonary fibrosis.

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Despite its established use in other conditions, the antibody is not yet approved for COPD treatment in any nation ... of the antibody as an add-on therapy to inhaled triple therapy in individuals ...